Oric Pharmaceuticals, Inc.

ORIC · XNAS

CIK 1796280fmd_1TTHVG8Z2SECW158CEPDJ6RWQHManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2018 to Jun 30, 2026, 31 periods

Income Statement · Annual · Millions · USD
Line item	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Research and development	19	23	36	57	62	85	114	110
Total operating expenses	22	29	74	79	92	111	143	143
Operating income	(22)	(29)	(74)	(79)	(92)	(111)	(143)	(143)
Other non-operating income (expense)	1	2	0	0	3	10	15	14
Income tax expense	0	0	0	0	0	0	0	0
Net income	(21)	(27)	(74)	(79)	(89)	(101)	(128)	(129)